Yunnan Cancer Hospital

Introduction

Yunnan Cancer Hospital was established in 1984. In 2021, it was approved as a National Cancer Regional Medical Center project. In June 2024, the Yunnan Hospital of Peking University Cancer Hospital (National Cancer Regional Medical Center) was inaugurated at the hospital. The hospital is a Grade III Level A cancer specialty hospital in Yunnan Province integrating medical services, education, research, and prevention. It undertakes tasks in cancer prevention and treatment research, talent cultivation, and academic exchanges in oncology. It houses 12 major medical centers including the Yunnan Cancer Center and the Yunnan Cancer Diagnosis and Treatment Quality Control Center. It serves as a National Health Commission base for early cancer detection and treatment, a continuing education base for oncology in Yunnan, an international cooperation demonstration base for lung cancer in Yunnan, and a national drug clinical trial institution (oncology). The main campus covers an area of 79 mu (approx. 5.27 hectares) with a total floor area of 246,000 square meters. It has 31 clinical departments, 12 medical technology departments, and 1,498 approved beds. The under-construction Cancer Center project is located on the north side of the main campus, covering 24 mu (approx. 1.6 hectares), with a planned investment of 1.85 billion RMB and 693 beds, expected to be operational in 2026. The under-construction Free Trade Zone Campus is located in the Economic Development Zone, with a total area of 119 mu (approx. 7.93 hectares) and 600 beds, expected to be operational in 2025. Phase I covers 69 mu (approx. 4.6 hectares) with a total floor area of 135,000 square meters, while Phase II reserves 50 mu (approx. 3.33 hectares) for the future construction of a proton and heavy ion center. The hospital is equipped with internationally advanced diagnostic and treatment equipment such as the Da Vinci surgical robot, intraoperative radiotherapy, CyberKnife, PET-MR, and PET-CT, and its cancer diagnosis and treatment technology is at the leading level in Yunnan Province. The hospital currently has 2,882 employees, including 194 with doctoral degrees, 784 with master's degrees, and 415 with senior professional titles. Among them are 1 Changjiang Scholar Distinguished Professor, 1 National Outstanding Youth Science Fund recipient, 2 leading talents of the National Ten Thousand Talents Program, 2 recipients of the National Hundred, Thousand, and Ten Thousand Talents Project, 7 recipients of the State Council Special Allowance, and 2 National Outstanding Science and Technology Workers. There are 89 individual awards and 10 team awards under the "Xingdian Talents Support Program"; 24 recipients of provincial-level special allowances; and 33 young and middle-aged academic and technical leaders, reserve talents, and technological innovation talents in Yunnan Province. In recent years, medical services have grown rapidly, with all business indicators maintaining a positive trend. In 2024, total outpatient and inpatient visits exceeded 1 million for the first time, a year-on-year increase of 18.26%. Surgical procedures reached 32,700, up 0.93% year-on-year, with surgeries accounting for 34.41% of total visits (up 3.09%) and Grade IV surgeries accounting for 50.93% (up 2.04%). The CMI value was 1.2996. The proportion of patients from outside Kunming reached 81.57%, a significant increase from the previous year. The hospital ranks first in the province in surgical volumes for lung, breast, colorectal, and gastric malignancies. The hospital has established a specialized system for cancer prevention, screening, diagnosis, and treatment with advanced diagnostic technologies and comprehensive treatment methods. Three specialties—Oncology, Thoracic Surgery, and Gastrointestinal Surgery—have been approved as National Key Clinical Specialties, and 17 specialties including Breast Surgery, Gynecology (Gynecologic Oncology), and Radiation Oncology have been approved as Provincial Key Clinical Specialties. It has been approved as a pilot construction project for the clinical collaboration of Chinese and Western medicine in major and difficult diseases (lung cancer) in Yunnan Province, and as a national pilot unit for standardized diagnosis and treatment quality control for 12 single diseases including lung cancer and liver cancer. The Molecular Diagnosis Center and the Medical Laboratory have passed the review and assessment of the China National Accreditation Service for Conformity Assessment (CNAS), and the hospital is qualified as a stem cell clinical research filing institution. In 2018, the hospital established the only internet hospital based on a physical hospital in Yunnan Province—the Yunnan Cancer Hospital Internet Hospital—actively exploring new models of internet-based diagnosis and treatment to help more patients overcome difficulties in accessing medical care. As a member of the National Cancer Specialty Alliance and the chair unit of the Yunnan Cancer Specialty Alliance, the alliance now includes 171 member units. The hospital has also established remote medical service collaboration relationships with multiple tertiary hospitals and county-level hospitals. In 2024, it joined the "China Oncology Clinical Research Medical Ethics Review Mutual Recognition Consortium" as one of the 20 founding members. The hospital has 8 key laboratories, 10 provincial-level innovation teams, 10 research centers, 4 academician workstations, and 10 expert workstations. It is the postdoctoral research workstation of the Third Affiliated Hospital of Kunming Medical University. Over the past five years, it has undertaken 792 research projects, published over 900 high-level papers in journals such as SCI and Peking University core journals, and obtained 14 invention patents. In the past five years, it has won a total of 20 scientific research awards, including 7 provincial-level science and technology progress awards and 13 departmental-level awards. As a directly affiliated hospital of Kunming Medical University, it has 12 teaching and research sections, 41 doctoral supervisors, and 237 master's supervisors. Using a "complementary teaching alliance between specialized and general hospitals," it provides "through-type" training for clinical medicine students. It is a national first-class undergraduate clinical medicine program construction site and a national standardized residency training base with two specialties: radiation oncology and clinical pathology. It has formed a talent training system covering undergraduate, master's, doctoral, post-graduation education, continuing medical education, and international student training. As a national regional medical center construction project unit, the hospital actively serves and integrates into the national development strategy, expanding external exchanges and service capabilities. Over 80% of its patients come from outside Kunming and even from other countries. It treats a large number of patients from neighboring provinces and autonomous regions such as Guizhou, Sichuan, Guangxi, and Tibet. In 2025, as one of the first batch of Yunnan Provincial International Medical Service Pilot Hospitals, the hospital established an International Diagnosis and Treatment Department, attracting a large number of patients from countries along the Belt and Road Initiative such as Bangladesh, Vietnam, Myanmar, and Laos. As a pilot hospital for modern hospital management systems, the hospital continuously advances the modernization of its governance system and capabilities, significantly enhancing its comprehensive strength, core competitiveness, and informatization level. It has passed the National Health Commission's Smart Management Grading Evaluation Level 2, Electronic Medical Record System Function Application Level 6, Interconnectivity Standardization Maturity Level 4A, and Smart Service Level 3 assessments. It has received honors such as National Advanced Collective in Cancer Prevention and Treatment, National People's Trusted Demonstration Hospital, National People's Trusted Top 100 Demonstration Hospital, National Humanistic Caring Hospital, National Outstanding Provincial Quality Control Center, National Advanced Collective in COVID-19 Prevention and Control in the Health System, National Women's Civilization Post, and Yunnan Provincial Advanced Collective in Health. In the future, the hospital will adhere to the tenet of "patient-centered, wholeheartedly serving cancer patients" and the motto of "benevolence in heart, diligence in work, excellence in skill," striving to build a high-level cancer medical highland that is first-class in western China, nationally leading, and radiating to South and Southeast Asia.